Vol 28, No 3 (2021)
Research Letter
Published online: 2021-03-24

open access

Page views 1272
Article views/downloads 1216
Get Citation

Connect on Social Media

Connect on Social Media

Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis

Milosz J. Jaguszewski1, Aleksandra Gasecka23, Radoslaw Targonski14, Krzysztof J. Filipiak2, Lukasz Szarpak56
Pubmed: 33843036
Cardiol J 2021;28(3):492-493.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Pathak A, Lebrin M, Vaccaro A, et al. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther. 2013; 38(5): 341–349.
  2. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007; 50(3): 257–263.
  3. Harjola VP, Giannakoulas G, von Lewinski D, et al. Use of levosimendan in acute heart failure. Eur Heart J Suppl. 2018; 20(Suppl I): I2–II10.
  4. Yaman M, Arslan U, Kaya A, et al. Levosimendan accelerates recovery in patients with takotsubo cardiomyopathy. Cardiol J. 2016; 23(6): 610–615.
  5. Bayram M, De Luca L, Massie MB, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005; 96(6A): 47G–58G.
  6. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000; 102(18): 2222–2227.
  7. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5: 13.
  8. Tycińska A, Gierlotka M, Bugajski J, et al. Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society. Kardiol Pol. 2020; 78(7-8): 825–834.